and its antibody asset Mim8, with the Phase III FRONTIER2 trial (NCT05053139) in haemophilia A completing earlier this year. Novo Nordisk has not yet published data from the study. Novo Nordisk is ...

A final decision is expected soon. Beyond diabetes and obesity, Novo Nordisk is diversifying its portfolio by developing Mim8 for hemophilia A, with plans to submit it for regulatory approval soon.

Novo Nordisk is diversifying its portfolio with treatments like Mim8 for hemophilia A. Mim8 has shown statistical significance in reducing treated bleeding episodes compared to no prophylaxis ...